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Abstract
Extracorporeal membrane oxygenatioon (ECMO) is a technique for providing life support, in
case the natural lungs are failing and are not able to maintain a sufficient oxygenation of the
body’s organ systems. ECMO technique was an adaptation of conventional cardiopulmonary
bypass technique and introduced into treatment of severe acute respiratory distress syndrome
(ARDS) in the 1970s. The initial reports of the use of ECMO in ARDS patients were quite
enthusiastic, however, in the following years it became clear that ECMO was only of benefit in
newborns with acute respiratory failure. In neonates treated with ECMO, survival rates of 80%
could be achieved. In adult patients with ARDS, two large randomized controlled trials (RCTs)
published in 1979 and 1994 failed to show an advantage of ECMO over convential treatment,
survival rates were only 10% and 33%, respectively, in the ECMO groups. Since then, ECMO
technology as well as conventional treatment of adult ARDS have undergone further
improvements. In conventional treatment lung-protective ventilation strategies were introduced
and ECMO was made safer by applying heparin-coated equipment, membranes and tubings.
Many ECMO centres now use these advanced ECMO technology and report survival rates in
excess of 50% in uncontrolled data collections. The question, however, of whether the
improved ECMO can really challenge the advanced conventional treatment of adult ARDS is
unanswered and will need evaluation by a future RCT. 
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Introduction
Acute respiratory failure, which is defined as the neces-
sity for intubation and mechanical ventilation, occurs with
an incidence of 78–88 cases/100000 inhabitants per
year [1,2]. The more severe forms of acute respiratory
failure, such as acute lung injury and acute respiratory
distress syndrome (ARDS), occur with incidences of
18–70 [1,3,4] and 1.5–13.5/100000 inhabitants per
year [1,2,5–8], respectively. Patients with ARDS respond
favourably to advanced methods of intensive care, which
include, but are not limited to, various forms of mechani-
cal ventilation with positive end-expiratory pressure
(PEEP) and permissive hypercapnia, positional manoeu-
vres, sophisticated fluid regimens and inhalational pul-
monary vasodilators [9–11]. In specialized centers that
apply these therapeutic options, encouraging survivalhttp://ccforum.com/content/4/3/156
rates of greater than 60% have been reported in uncon-
trolled trials [10,12–15].
There remains, however, a small number of ARDS patients
whose pulmonary gas exchange can not be improved suf-
ficiently by the above mentioned methods, and extracorpo-
real membrane oxygenation (ECMO) may then be an
additional therapeutic option during the acute phase. This
review discusses the rationale, history, technique and
outcome of this demanding procedure.
Rationale of extracorporeal membrane
oxygenation
During the past few decades it has become evident from
laboratory and clinical research that, in patients with acute
lung injury, mechanical ventilation contributes to the pro-
gression of the disease. To describe the nonspecific radio-
graphical, physiological and pathological manifestations of
acute lung injury and its complications, the term ‘ventilator-
induced lung injury’ was coined [16]. Ventilator-induced
lung injury, for years used synonymously with barotrauma of
the lung, is currently viewed as a systemic disease with
similar symptoms and macroscopical and microscopical
features of experimental acute lung injury, which is not
markedly different from the diffuse alveolar damage that is
present in human ARDS. It may be associated with pul-
monary and systemic infections, multisystem organ dys-
function, volutrauma, barotrauma and increased mortality.
Animal studies [17,18] have shown that mechanical ventila-
tion involving the application of high airway pressures or
large tidal volumes (VTs) in combination with too high or too
low PEEP may generate shear forces that effect healthy or
diseased lungs, and can increase capillary permeability,
promote gas leaks and oedema, and initiate inflammation.
Results of a study in an isolated rat lung model [19] suggest
that mechanical ventilation can induce activation and influx
of neutrophil granulocytes and liberation of cytokines,
leading to local and systemic inflammatory reactions. These
findings were recently reproduced in human ARDS. Ranieri
et al [20] found that ARDS patients who were mechanically
ventilated with VTs of 11.1ml/kg body weight and an end-
inspiratory plateau pressure of 31.0cmH2O had signifi-
cantly higher concentrations of inflammatory mediators than
did patients who were mechanically ventilated with smaller
VTs of 7.6ml/kg body weight and an end-inspiratory plateau
pressure of 24.6cmH2O.
These insights were paralleled by implementation of the
‘protective ventilation strategy’ in critical care of patients
with severe acute respiratory failure [9]. This therapeutic
concept is aimed at shielding the diseased, ventilated lung
by applying only small VTs. Establishing a ‘lung-protective
ventilation strategy’ in severe ARDS may be incompatible
with the goal of maintaining sufficient gas exchange.
ECMO is able to partly take over oxygenation and carbon
dioxide removal, and thereby may allow respirator settings
(peak inspiratory pressure, VT, PEEP, respiratory rate, frac-
tional inspired oxygen) to be adjusted to the mechanical
and gas exchange properties of the diseased lung. In this
way the goals of lung protective mechanical ventilation
can be reached, even in severe ARDS.
History
In 1885, von Frey and Gruber [21] developed the first
device to oxygenate blood extracorporally for perfusion of
isolated organs. Gas exchange was achieved by conduct-
ing a continuous flow of oxygen through an inclined rotat-
ing cylinder, the inner surface of which was covered with a
thin film of blood. Gibbon [22] began developing the
heart–lung machine in 1937 in order to allow open heart
surgery to be performed. He designed a system in which
anticoagulated blood was directly exposed to oxygen
(‘film’ or ‘bubble oxygenators’). Due to the direct contact
between blood and the gaseous phase, however, severe
haemolysis, thrombocytopaenia, haemorrhage and organ
failure complicated the treatment and limited the use of
this device to a few hours [23]. In 1956, Clowes et al [24]
developed an artificial lung that separated the gaseous
from the liquid phase by a membrane. This ‘membrane
oxygenator’, with subsequent improvements in materials,
provided faster and more efficient blood oxygenation with
fewer complications than the ‘film’ or ‘bubble oxygenators’,
and became practical for cardiopulmonary bypass that
lasted longer than a few hours [25]. In 1972, clinical appli-
cation of ECMO in respiratory failure of newborns and
adults was attempted. In that year, Hill et al [26] reported
the survival of a 24-year-old polytraumatized patient with
ARDS who had been treated with ECMO during the acute
phase of the disease. Four years later, Bartlett et al [27]
reported on baby Esperanza, the first newborn treated
with ECMO, who survived.
These enthusiastic reports nourished the hope that an
effective new symptomatic therapy for severe hypoxia in
ARDS was available. A large randomized multicenter trial
was launched in 1974 to test venoarterial ECMO versus
conventional therapy in adult ARDS patients [28]. The
study revealed that mortality rates in the ECMO therapy
group were as high as 90% and not significantly different
from those in the conventionally treated group. These dis-
couraging results in adult ARDS patients dampened previ-
ous enthusiasm, and interest in venoarterial ECMO waned
in most research groups.
The idea of supporting impaired lung function with extra-
corporeal gas exchange in adults, however, was subse-
quently pursued by Kolobow et al [29]. The rationale of
their advanced technique was to prevent further damage
to the diseased lungs by reducing their motion (pulmonary
rest) with application of only a few ventilator breaths with
low VT and low peak inspiratory pressures. This lung pro-Critical Care    Vol 4 No 3 Lewandowski
tective mechanical ventilation strategy became known as
low-frequency positive-pressure ventilation (LFPPV) [30].
With this method, oxygen uptake and carbon dioxide
removal were dissociated. Oxygenation was primarily
accomplished through the nearly motionless natural lung
via apneic oxygenation, and carbon dioxide was cleared
through the artificial lung [extracorporeal carbon dioxide
removal (ECCO2-R)]. The so-called LFPPV–ECCO2-R
technique was performed at low extracorporeal blood
flows (20–30% of cardiac output), so that a venovenous
bypass technique instead of an arteriovenous one suf-
ficed, which turned out to be less detrimental to blood
cells, coagulation and internal organs. Using LFPPV–
ECCO2-R, Gattinoni et al [30] reported survival rates of
up to 49%. In the following years several centres corrobo-
rated the promising survival rates of around 50% and
higher (Fig. 1); these were uncontrolled observations that
needed further confirmation in RCTs.
These positive results from European centres were noted
in the USA, and the refined ECMO technique was again
taken into consideration for treatment of severe ARDS in
adults. In 1994, Morris et al [31] reported the results of a
RCT performed in a pulmonary intensive care unit of the
Latter Day Saints Hospital in Salt Lake City, which tested
the altered ECMO technique against advanced standard
treatment. They compared pressure-controlled inverse
ratio ventilation (pcCMV-IRV) followed by LFPPV–
ECCO2-R with controlled positive-pressure ventilation in
patients with ARDS. They found that survival was not sig-
nificantly different between the groups (42% conventional
therapy versus 33%), although overall survival rate had
improved significantly when compared with the results
from the US ECMO study of 1974 [28]. The authors rec-
ommended that ECMO should not be used for the treat-
ment of adult ARDS.
ARDS treatment centres in Europe, however, believed that
the potential of ECMO to improve the severely impaired
gas exchange during the acute phase of the disease was
an important factor contributing to the good survival rates
in excess of 50% that were found in uncontrolled studies.
Clinicians wondered why the RCT of Morris et al [31] did
not result in better survival rates in the ECMO group.
Several explanations have been forwarded. Habashi et al
[32] pointed out that the ventilatory management in the
ECMO group was not uniform and may have altered
patient outcome, because the first half of the patient
group had peak airway pressures controlled and the latter
half had VTs controlled. Brunet et al [33] commented that
the ventilatory management in the ECMO group did not
significantly differ from that in the control group, in which
peak inspiratory pressures that were higher than the
maximum recommended levels [34] were employed. Fur-
thermore, a considerable amount of criticism was directed
at the ECMO technique used in the trial by Morris et al
[31]. Most reviewers agree that the ECMO methodology
was not optimized and did not achieve modern standards
[32,33,35–37]. The untypically high blood loss complica-
tion rate associated with ECMO therapy [32,35–37] was
considered to be an indicator of antiquated ECMO tech-
nology without heparin-coated equipment.
Bleeding due to complete anticoagulation has been
reported as the major complication during extracorporeal
respiratory support [38–40]. In 1983, Larm et al [41]
developed a technique in which the heparin molecule is
covalently attached to synthetic surfaces, which allowed
heparinization of all surfaces of the extracorporeal gas
exchange device that come into contact with blood. In
1987, Bindslev et al [42] reported the first long-term appli-
cation of a surface-heparinized extracorporeal circuit in a
44-year-old woman with severe ARDS. Since that time,
nearly all European ECMO centres have switched to the
surface-heparinized extracorporeal circulation technique,
with no or minimal systemic heparinization [10,43].
Terminology
Several terms have been used to describe the variety of
techniques that have been designed to oxygenate blood
and remove carbon dioxide extracorporally. When the term
‘ECMO’ was coined in the 1970s, it was used to refer to a
high-flow venoarterial bypass system that was aimed pri-
marily at blood oxygenation [28]. In the 1980s, when
Kolobow et al [29] developed their low-flow venovenous
bypass technique for extracorporeal gas exchange, the
term ECCO2-R instead of ECMO came into use to under-
score the importance of elimination of carbon dioxide in
Figure 1
ARDS patients treated with ECMO in European centres from 1992 to
1998. Data were obtained by a yearly fax survey among the centres. In
1995 the number of centres participating in the survey had almost
doubled, as did the number of ECMO therapies. Since 1996 the
frequency of ECMO therapies in Europe has been decreasing. Survival
rates in ECMO patients have remained constant at above 50% during
the past 6 years.this method. For patients with chronic lung diseases, Mar-
colin  et al [44] established a technique termed ‘partial
extracorporeal carbon dioxide removal’ (PECOR). Its goal
is to eliminate only part of the body’s carbon dioxide load.
In 1987, a Japanese working group introduced the term
‘extracorporeal lung assist’ (ECLA), to describe a venove-
nous low-flow bypass system that is used in patients who
were not endotracheally intubated and mechanically venti-
lated [45]. In an effort to simplify and reduce terminology to
a common denominator, Zwischenberger and Bartlett [46]
proposed the term ‘extracorporeal life support’ (ECLS), to
describe prolonged but temporary (1–30 days) support of
heart or lung function using mechanical devices.
The typical bypass circuit currently employed in ARDS
patients is a low-flow venovenous bypass circuit, but
occasionally cardiac support is also an issue, and in such
circumstances the intensivist will change to a venoarterial
setting. This ‘flexible’ handling of the extracorporeal circuit
incorporates the whole spectrum of advanced bypass
techniques, so who decides when exactly PECOR ends
and ECCO2-R begins, or when ECCO2-R changes to ven-
ovenous ECMO? In part, it was these problems in termi-
nology that allowed the acronym ECMO to survive the
changing technologies. What is more, ECMO has become
a general byword for the wide range of methods that are in
use for extracorporal blood oxygenation and carbon
dioxide removal. More important than the question of
which acronym to use, however, should be the exact char-
acterization of the applied extracorporeal circulation and
pulmonary support system. Pesenti et al [37] suggested a
minimum of three criteria: the vascular access used (veno-
venous, venoarterial or arteriovenous); the proportion of
cardiac output pumped; and the ventilatory regimen of the
natural lung.
Extracorporeal membrane oxygenation
technique
In the typical low-flow venovenous bypass that is fre-
quently used at present, as in our ECMO centre [10],
venous blood is drained through two heparin-coated,
28-gauge, wire-reinforced catheters that are percuta-
neously inserted from both sides of the groin area into the
inferior vena cava and then connected by a Y-piece. The
oxygenated blood is returned into the superior vena cava
through a 20-gauge, heparin-coated, wire-reinforced
catheter, which is advanced percutaneously via the right
internal jugular vein. A femoral–jugular venovenous bypass
is established using a near-occlusive roller pump and a
parallel configuration of two hollow fibre oxygenators.
Figure 2 shows an ECMO circuit. All internal surfaces of
the extracorporeal system, including the membrane oxy-
genators, are coated with covalently bound heparin. The
system is primed with packed red blood cells and fresh
frozen plasma at a ratio of 2:1. The gas phase of the oxy-
genator is initially flushed with dry pure oxygen. The gas
flow rate is set to the required arterial carbon dioxide
tension levels. Oxygenation is accomplished through the
mechanically ventilated natural lung as well as by arterializ-
ing the circulating blood via the membrane oxygenator.
The ECMO technique and the setup described above is
just one possible approach; some groups use modifica-
tions of this circuit.
Complications associated with extracorporeal
membrane oxygenation
Known hazards of the ECMO technique can be classified
into mechanical and patient–medical complications.
Mechanical complications include oxygenator failure,
tubing/circuit disruption, pump or heat exchanger malfunc-
tion, and problems associated with cannula placement or
removal. Patient-related medical problems are bleeding,
neurological complications, additional organ failure (eg
renal, cardiovascular, liver), barotrauma, infection and
metabolic disorders.
Data regarding the frequency of complications associated
with ECMO in adult ARDS patients are provided by the
Extracorporeal Life Support Registry [47]. In 95 adult
ARDS patients, a total of 68 mechanical and 302 patient-
related complications occurred during bypass. Further
information regarding technical complications experienced
in extracorporeal respiratory support in adult ARDS
patients is given by Gattinoni et al [48]. In 22000 h of
bypass, no life-threatening technical complications
occurred. During 27137 h of ECMO bypass, we regis-
tered a total of 27 technical complications, among which
pump malfunction (n=6), tubing rupture (n=6), and
http://ccforum.com/content/4/3/156
Figure 2
Schematic drawing of a low-flow venovenous ECMO circuit.Critical Care    Vol 4 No 3 Lewandowski
cannula placement or removal problems (n=5) were the
most frequent [10]. Available literature, however, suggests
that bleeding remains the most frequent complication in
adult patients with ARDS who are undergoing extracorpo-
real gas exchange, and seems partly related to constant
intravenous heparinization [38,39,48–53]. In a prospec-
tive randomized controlled study, Knoch et al [54] sug-
gested that the use of surface-heparinized ECMO circuits
and membranes reduces the daily blood loss, the amount
of substituted red cells and the necessary intravenous
heparin dose. Survival rate was higher than that in patients
treated with nonheparinized systems. Pesenti et al [37]
also report a significantly reduced requirement of packed
red blood cells, which they attributed to the use of a
heparinized ECMO circuit.
Patient selection criteria
The criteria for treatment with ECMO in adults vary substan-
tially among centres (Table 1). They are usually modifica-
tions of the classic fast and slow entry criteria of the US
ECMO study [28], and typically include an oxygenation cri-
terion that is assessed at certain time points during the
acute phase of the disease at a specific respirator setting,
the compliance of the lung, and sometimes extravascular
lung water and a pulmonary scoring system. More consen-
sus exists regarding exclusion criteria. Widely accepted
exclusion criteria are as follows: contraindication to antico-
agulation, irreversible damage to the central nervous
system, severe chronic pulmonary disease, extremely poor
prognosis due to underlying disease (eg terminal cancer),
immunosuppression, multiple organ failure and left
ventricular failure. Currently, with increasing use of surface-
heparinized ECMO equipment, contraindication to anti-
coagluation as an exclusion criterion for ECMO requires
reconsideration. Definite clinical testing of the ECMO tech-
nique requires a consensus on reasonable, standardized
inclusion and exclusion criteria among centres.
Outcome from extracorporeal membrane
oxygenation
ARDS was first described by Ashbaugh et al in 1967 [55].
They reported a 58% mortality rate in 12 patients present-
ing with the syndrome. During the following years, several
new mechanical ventilation modes and therapeutic mea-
sures, as well as ECMO, were introduced into the therapy
for ARDS. Gille and Bagniewski [56] collected data on the
first 10 years of use of ECMO in the treatment of acute
respiratory insufficiency. From 1966 to 1975, 233 ARDS
patients were treated with ECMO by 90 medical teams in
seven countries. The cumulative survival rate was 15%.
No standardized entry and perfusion criteria were used,
there were variations in utilization of cannulation modes,
and different membrane oxygenators were employed. The
results of the 1974 US ECMO trial [28] confirmed this
disappointing survival rate; they showed a survival rate of
only 10% in the ECMO group.
Since the 1980s, however, reports have been published
that note quite acceptable survival rates of 40–50% in
patients treated with the refined ECMO technique, the so-
called LFPPV–ECCO2-R method. Gattinoni et al [30]
found a survival rate of 49% in 1986. Through July 1995,
the Extracorporeal Life Support Organization Register in
Ann Arbor, Michigan, USA recorded an overall survival
rate of 41% in 197 adult ARDS patients treated with
extracorporeal respiratory support [57]. In Europe, no
such register exists, but since 1992 survival data of
ECMO treated ARDS patients have been collected via an
annual fax survey (Fig. 1). From 1992 to 1999, more than
850 patients with acute respiratory distress syndrome
were treated with ECMO, and survival rates around 50%
have been achieved. These survival rates, although
coming from uncontrolled data collections, differ greatly
from the 10% survival of the 1974 US ECMO trial [28].
The US ECMO trial was only the first of two RCTs that
tested ECMO versus standard therapy. The US ECMO
trial of 1974 [28] applied the original venoarterial ECMO
technique, the second ECMO trial, which was performed
from 1987 to 1991 by Morris et al [31], employed the
LFPPV–ECCO2-R technique. Although both RCTs did not
find significant differences in the survival rates between
ECMO and conventionally treated patients, the overall sur-
vival rate had improved significantly when comparing the
results obtained in 1974 (survival rates of 10 and 8%,
respectively) with those from 1994 (survival rates of 33
and 42%, respectively). Improvement in survival rates of
conventionally treated ARDS patients was also observed
by one US centre [12] and two European centres [13,15].
The studies used different methodologies and reported
that survival had improved considerably in recent years
compared with historical controls, taking into account
severity of illness and adjusting for other variables.
In response to these findings, several editorials and
reviews [58–60] have expressed an optimistic view
toward improvement in survival rates in ARDS. Schuster
[61] reviewed 14 major ARDS studies regarding outcome
and concluded that mortality rates are decreasing. Krafft
et al [62], however, after evaluating 101 peer-reviewed
studies published between 1967 and 1994, came to the
conclusion that no changes in outcome can be detected.
The most recent data on survival in ARDS were offered by
Zilberberg and Epstein [63] and Monchi et al [64]; they
reported survival rates in ARDS patients of 42 and 35%,
repectively. Luhr et al [1] reported the first large multicen-
tre trial, however, in which a survival rate of as high as
59% was assessed.
Figure 3 presents the trends in reported survival rates of
ARDS since 1966 in two treatment groups (conventionally
and ECMO-treated patients). The reported survival rates
in conventionally and ECMO treated ARDS patientshttp://ccforum.com/content/4/3/156
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appear to have improved and converged over time. My per-
sonal belief is that survival rates in conventionally treated
ARDS patients and in ECMO-treated ARDS patients have
improved since 1967. However, the problem in evaluating
potential improvements in survival rates of ARDS derives
from the long-standing heterogeneity and lack of definitions
for the underlying disease processes, the lack of a uniform
definition for ARDS, the various therapies applied, and
indistinct definitions of study populations [65].
Long-term follow up of survivors from ARDS
who were treated with ECMO
Given the catastrophic degree of respiratory failure, the
acute pathological findings (including interstitial fibrosis)
[66], the high mortality and the high costs of treating these
patients {US$120800 (UK£75500) per patient for therapy
with ECMO, US$97200 (UK£60750) per patient for con-
ventional treatment [31]}, what is the long-term recovery of
those who do survive? Regarding conventionally treated
patients, most authors agree that the very poor short-term
prognosis of ARDS is outweighed by the chance of nearly
complete recovery, although different patterns and grades
of respiratory dysfunction were found. The most frequently
noted disorder is a reduction in the diffusing capacity of
carbon monoxide, but in other articles remaining pathologi-
cal lung volumes, expiratory flow rates and gas exchange
impairments are documented [67]. All in all, the results of
quality of life investigations appeared satisfactory [68–70],
until Hopkins et al [71] very recently reported results on
cognitive and psychological outcomes in ARDS survivors.
They studied 55 consecutive patients and found that, at
hospital discharge, 100% exhibited cognitive and affective
impairments, as well as problems with health status that
affected their quality of life. One year after ARDS, 30% of
the patients still showed generalized cognitive decline.
What degree of recovery can be expected in ARDS
patients treated with ECMO? One could assume that
ARDS patients treated with ECMO have suffered from
severe lung injury, and therefore that only incomplete
recovery might be likely. On the other hand, patients
treated with ECMO may be protected from the damaging
effects of mechanical ventilation.
Only few authors have investigated larger populations of
ARDS patients who had been treated with extracorporeal
respiratory support. Knoch et al [72] investigated lung func-
tion and recovery in 38 ARDS survivors whose pulmonary
gas exchange had been supported by ECMO. Within the
third and sixth month after hospital discharge, the forced
expiratory volume in 1 s and arterial oxygen tension levels
reached the lower range of normal values. The ratio of resid-
ual volume:total lung capacity (a measure of relative lung
emphysema) was 167% of normal at the time of discharge
from the hospital, and had decreased to 114% of normal
after a further 3 months. This was found to reverse during
the following months. All patients had an abnormal diffusion
capacity with normal transfer coefficients for carbon monox-
ide 12–20 months after hospital discharge. Impaired diffu-
sion capacity and the reduced forced expiratory flow
between 25 and 75% of expiration (62.5±25.0% of pre-
dicted at 12–20 months after hospital discharge) indicated
residual changes in the small airways. At that time, chest
radiography and computed tomography scans of the lungs
revealed various minor morphological residuals only. Car-
diopulmonary function during spiroergometry showed
values normal for untrained individuals. Within 12–20
months after discharge, 36 out of the 38 patients had
returned to normal working and social activities.
Stoll et al [73] investigated the health-related quality of life
using the Medical Outcomes Study 36-Item Short-Form
Health Survey [74] in 14 patients who survived ARDS and
had been treated with ECMO. Long-term survivors of ECMO
therapy reported significant reductions in physical function-
ing when compared with other mechanically ventilated
ARDS patients or healthy control individuals, and showed a
higher incidence of chronic physical pain. There were no dif-
ferences with regard to the mental health dimensions of the
36-Item Short-Form Health Survey between ECMO patients
and control individuals. Of the ECMO group 64.3%, but all
patients treated conventionally had full-time employment.
Extracorporeal membrane oxygenation in
neonates and children
ECMO technology has been developed and improved
during the past 3 decades. In its infancy, in the 1970s,
Figure 3
Trends in reported survival rates in conventionally (non-ECMO) and
ECMO-treated ARDS patients, including data from 51 clinical studies.
Reported survival rates in (s) conventionally treated and (j) ECMO-
treated ARDS patients. The survival rate reported in each study was
assigned to the year representing the median of study period or, if the
study period was not stated, to the year of report. The data support the
view that survival rates in both treatment groups followed a positive
trend. Data have been taken from [1,5,8–10,12–15,30,31,39,43,55,
56,63,64,91,92,95,96,101–130].ECMO was most commonly used to support mature
newborn infants with acute respiratory failure. In neonates,
quite promising survival rates of 56% have been observed
since ECMO was introduced into treatment [75], whereas
in adults comparable good survival rates were lacking
[28]. Bartlett et al [76] attributed the success of ECMO in
newborns to the fact that in neonatal respiratory failure the
lungs require only a short time for recovery, and extracor-
poreal techniques in the 1970s could be carried out safely
for a few days. In the 1980s, the technology was adapted
to paediatric and, later on, in the 1990s, to adult acute
respiratory failure and cardiac failure.
In the neonate, persistent pulmonary hypertension (PPHN)
is the most frequent cause of acute respiratory failure. The
aetiology of PPHN can either be idiopathic or a secondary
consequence of a variety of diseases that include, but are
not limited to, sepsis, pneumonia, meconium aspiration,
diaphragmatic hernia and hyaline membrane disease. PPHN
is pathophysiologically characterized by the distinct pul-
monary hypertension, pronounced hypoxia and the extrapul-
monary right-to-left shunt across the patent ductus
arteriosus and the foramen ovale. The course of the disease
may be complicated by the effects of direct lung damage,
leading to additional intrapulmonary right-to-left shunt.
Conventional treatment includes mechanical ventilation
with high inspired fractional oxygen, hyperventilation, intra-
venous bicarbonate and vasodilators, as well as instillation
of surfactant. Advanced concepts involve replacing simple
intermittent positive pressure ventilation by high-frequency
oscillatory ventilation, and adding inhalation of nitric oxide
(NO) to the therapeutic armamentarium [77]. Additionally,
ECMO has been used to relieve hypoxaemia and had
become standard practice in many neonatal centres by
1988 [78]. The registry of the Extracorporeal Life Support
Organization [79] reported an 80% survival rate in 10391
patients with neonatal respiratory failure who were treated
with ECMO from 1980 to 1995. Bartlett et al [76] recently
reviewed the worldwide experience with ECMO, and
pointed out that ECMO for severe respiratory failure in
neonates has been evaluated in four prospective random-
ized trials [80–83] and one uncontrolled study [84]. The
survival rates reported in those trials are presented in
Table 2. All neonatal studies showed that survival rates
after ECMO were much better than those achieved with
conventional therapy.
In the 1980s, the benefit of ECMO for paediatric patients
was subject to discussion [85,86]. Concerns mainly con-
centrated on the widely unknown mechanisms of pul-
monary injury in this patient group and the new, expensive
and potentially dangerous technology. Performance of a
RCT was considered mandatory before ECMO gained
further acceptance in children. Due to ethical considera-
tions, however, this approach was postponed. Instead, the
Extracorporeal Life Support Organization registry was
founded in 1989, and documented a cumulative survival
rate of 53% in 982 cases of paediatric respiratory failure
from 1990 to 1995 [79]. In these patients, respiratory
failure was caused by various direct and indirect lung
injuries such as pneumonia, aspiration, ARDS and others.
In 1996, Green et al [87] presented the results of a retro-
spective multicenter cohort analysis in 331 paediatric
patients, evaluating factors associated with survival with a
multivariate logistic regression analysis. The authors found
ECMO to be associated with a reduction in mortality. In an
additional matched-pairs analysis, they found that 74% in
the ECMO group (n=29) survived, and 53% in the non-
ECMO group (n=53; P<0.01).
The introduction of inhaled NO into the therapy of PPHN
has had a fundamental impact on both the therapeutic
approach and the mortality rates of neonates. The results
of at least four RCTs have been published to date, which
all demonstrated a decrease in the frequency of use of
http://ccforum.com/content/4/3/156
Table 2
Survival rates of neonatal ECMO
Control group ECMO group
Reference Year  Study design Patients total (n) n survival rate (%) n survival rate (%) P
[80] 1985 RCT ‘play the winner’* 12 1 0 11 100 Not reported
[82] 1989 RCT
(phase 1+2) 39 10 60 29 97 < 0.05
[81] 1993 RCT 41 19 89 22 91 NS
[83] 1996 RCT 185 92 41 93 68 < 0.001
[84] 1999 Uncontrolled study 100 – – 100 82 –
*Bartlett et al [80] used a special randomized play-the-winner statistical method; the chance of randomly assigning an infant to one treatment or the
other is influenced by the outcome of treatment of each patient in the study. If one treatment is more successful, more patients are randomly
assigned to that treatment.ECMO. Details of these studies are given in Table 3. The
data from the Extracorporeal Life Support Organization
[79] also show a decrease in the frequency of use of
ECMO beginning in 1993, which, according to the authors
(of the registry) may be attributed to the introduction of
new treatment options such as high-frequency oscillatory
ventilation, inhaled NO, or surfactant into clinical practice.
The greatest decrease in case volume coincided with the
use of exogenous surfactant, beginning in 1990.
Although the reported survival rates in neonates and chil-
dren appear to be impressive, ECMO therapy in these
patients is subject to specific complications. Major prob-
lems that need to be tackled in the near future include
neurological deficits that probably arise from cannulation
techniques, bleeding and technical complications during
running bypass, and hearing loss that possibly results from
medication during hospitalization (furosemide, antibiotics).
The total incidence of neurological deficits associated
with ECMO is 10% for neonates and 2% for children at
the time of hospital discharge [76].
Impact of new treatment strategies on the
requirement for ECMO
Recent studies suggest that mechanical ventilation with
too low or too high levels of PEEP, high airway pressures
and large VTs may further damage the injured lung and
cause ventilator-induced lung injury [16]. Lung-protective
mechanical ventilation attempts to shield the injured lung
by applying only small VT [88] and using adjunctive mea-
sures such as prone positioning [89], inhalation of NO
[11] and early spontaneous breathing [90].
Small VT ventilation was recently compared with large VT
ventilation in a RCT by the National Heart Lung and Blood
Institute organized ARDS network [88]. The effects of
reduced VTs of 6ml/kg body weight versus large VTs of
12ml/kg body weight were evaluated with regard to their
effects on mortality and other outcome parameters. After
inclusion of 841 intubated and mechanically ventilated
patients with acute lung injury or ARDS, the trial was
stopped because the mortality difference crossed a pre-
determined threshold. Estimated mortality at hospital dis-
charge was 30.4% in the low VT group and 39.8% in the
high VT group (P=0.0054). This trial showed that a low VT
ventilator strategy was associated with improved survival
in acute lung injury/ARDS patients. The results of other
recently conducted studies [9,91] also suggest that avoid-
ance of ventilator-induced lung injury may be associated
with increased survival rates.
A reduction in mortality rates in ARDS patients after treat-
ment with inhaled NO or prone positioning has not been
documented; however, significant improvements in dis-
tinct physiological parameters, such as arterial oxygen
tension/fractional inspired oxygen, pulmonary hyperten-
sion and intrapulmonary right-to-left shunt, were recorded
during the acute phase of the disease [11,89]. The new
therapies might therefore interfere with the ECMO entry
criteria, which are, in most centres, defined by gas
exchange and haemodynamic parameters (Table 1). Con-
sequently, ECMO is not considered as an additional
measure until the other therapeutic options are exhausted.
This approach may delay or exclude the decision for extra-
corporeal support [36]. In conclusion, the introduction of
new therapies and improvements in conventional ARDS
therapy have possibly changed the indications for ECMO
to include only the most severe cases of ARDS.
Recent data from our ARDS centre support this idea
because we have been observing a decreasing frequency
of ECMO treatment in adult ARDS patients within the past
few years (Fig. 4). Researchers are encouraged to investi-
gate this observation, because no studies in adults have
been performed to identify the cause of this phenomenon
definitively.
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Table 3
Reduction of ECMO frequency in newborns in four randomized
controlled studies
% ECMO in % ECMO
Study Patients the control in the NO
Reference Year design total (n) group group P
[97] 1997 RCT 58 71 40 0.02
[98] 1997 RCT 235 54 39 0.014
[99] 1998 RCT 155 34 22 0.12
[100] 2000 RCT 248 64 38 0.001
Figure 4
ARDS patients treated with ECMO at the Charité, Virchow Clinic,
Berlin. Since 1995/1996 the frequency of ECMO treatment in ARDS
patients has been decreasing, although the number of ARDS patients
admitted to the centre has remained almost constant.http://ccforum.com/content/4/3/156
Conclusion
ARDS is a rare disease; only 1–14 adults in 100000
develop the syndrome each year. The severely impaired gas
exchange that is the main and immediate life-threatening
characteristic of ARDS can be improved in most patients by
a lung protective therapeutic approach using mechanical
ventilation with PEEP and permissive hypercapnia, posi-
tional manoeuvres, a cautious fluid regimen and inhalational
pulmonary vasodilators. In a few patients the combined
application of all these measures fails to improve the gas
exchange, however, and continuous severe hypoxia, if not
prevented, may cause irreparable organ damage or death.
ECMO can symptomatically prevent severe hypoxia and
remove carbon dioxide until the patient’s lungs are able to
resume their gas exchange function. ECMO, in its principal
features, has been at our disposal since the 1970s, but
almost a quarter of a century was needed before the tech-
nology and indications had undergone the refinement that
guarantees successful and safe treatment of severe hypoxia
in adult ARDS. Today we know that the venovenous bypass
techniques are, in most cases, safer and more promising
than the arteriovenous methods. We now have modern
heparinized tubings and membrane oxygenators at hand,
which help us to avoid bleeding complications. European
working groups collected data from more than 850 adult
ARDS patients treated with ECMO and observed a survival
rate of greater than 50% (Fig. 1). These quite promising
data are uncontrolled, however. Two RCTs published in
1979 [28] and 1994 [31] failed to show an advantage of
ECMO over conventional treatment in adults. ECMO tech-
nique has undergone some improvement since these trials,
but the question of whether the improved ECMO can really
challenge conventional treatment of adult ARDS will need
to be answered by a future RCT, which has already been
scheduled [76].
In my opinion the expenditure on money, time and per-
sonal energy when treating a patient with ECMO is worth
the effort, because the majority of the survivors will
achieve a satisfying general health status, lung function
and quality of life 6–12 months after the acute phase of
the disease, and most of them can return to their former
social and working lives.
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